Related Experiment Video
Updated: Jul 13, 2026
08:36
Ultrasound Imaging-guided Intracardiac Injection to Develop a Mouse Model of Breast Cancer Brain Metastases Followed by Longitudinal MRI
Published on: March 6, 2014
Amyloid-related imaging abnormalities after immunotherapy: How might brain microvascular basement membrane components
Harry V Vinters1,2, Shino Magaki1
1Department of Pathology & Laboratory Medicine (Neuropathology), David Geffen School of Medicine at UCLA, & Ronald Reagan UCLA Medical Center, Los Angeles, CA, USA.
Journal of Alzheimer'S Disease : JAD
|July 11, 2026
Summary
Alzheimer's immunotherapy drug lecanemab may affect collagen in brain microvessels, potentially explaining vascular complications like ARIA-E and ARIA-H. This pilot study used human brain microvessels to investigate this mechanism.
Area of Science:
- Neuroscience
- Vascular Biology
- Biochemistry
Background:
- Basement membrane components are crucial for cerebral microvessel function.
- Alzheimer's disease immunotherapy, like lecanemab, can cause vascular complications (ARIA-E, ARIA-H).
Purpose of the Study:
- To investigate the potential mechanism of lecanemab-induced vascular complications.
- To examine the effects of lecanemab on collagen within human cerebral microvessel walls.
Main Methods:
- Utilized viable microvessels isolated from human Alzheimer's disease brains.
- Employed novel biochemical and molecular approaches to analyze microvessel components.
- Focused on the interaction between lecanemab and collagen in microvessel walls.
Main Results:
- Preliminary evidence suggests lecanemab influences a specific collagen component in cerebral microvasculature.
- Identified a potential mechanism linking lecanemab to microvessel wall changes.
Conclusions:
- Lecanemab may impact cerebral microvessel basement membrane components.
- Further studies are needed to fully understand lecanemab's vascular effects in Alzheimer's disease.
